Dannielle Appelhans
Director/Board Member chez GENERATION BIO CO.
Fortune : 81 400 $ au 31/03/2024
Profil
Dannielle Appelhans is currently the Director at Generation Bio Co. and the Chief Operating Officer at Cour Pharmaceuticals Development Co., Inc. Prior to her current positions, she was the President & Chief Executive Officer at Rubius Therapeutics, Inc. and the Chief Technical Officer at Novartis Gene Therapies, Inc. She holds a graduate degree from the Massachusetts Institute of Technology, an undergraduate degree from the University of Michigan, and an MBA from the MIT Sloan School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GENERATION BIO CO.
0,03% | 08/12/2023 | 20 000 ( 0,03% ) | 81 400 $ | 31/03/2024 |
Postes actifs de Dannielle Appelhans
| Sociétés | Poste | Début |
|---|---|---|
| GENERATION BIO CO. | Director/Board Member | 15/07/2022 |
Cour Pharmaceuticals Development Co., Inc.
 Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Chief Operating Officer | 19/07/2023 |
Anciens postes connus de Dannielle Appelhans
| Sociétés | Poste | Fin |
|---|---|---|
| RUBIUS THERAPEUTICS | Chief Executive Officer | 03/03/2023 |
| AVEXIS INC | Chief Tech/Sci/R&D Officer | 01/01/2021 |
Formation de Dannielle Appelhans
| Massachusetts Institute of Technology | Graduate Degree |
| University of Michigan | Undergraduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GENERATION BIO CO. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
Cour Pharmaceuticals Development Co., Inc.
Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL. | Health Technology |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
